The mission of the Cancer Biology Laboratory is to develop smart cancer therapeutics with increased potency and decreased side effects.
We use phage display screens to identify homing peptides that bind to specific targets in the vasculature. Corresponding synthetic peptides are explored for targeting drugs, biologicals, and nanoparticles into tumors to increase their therapeutic index. Our scope includes understanding the molecular interactions involved to drive specificity and activity, focusing on Tumor Penetrating Peptides (TPP) that trigger bulk extravascular transport in the tumor tissue.
Research Day of the Department of Biomedicine (March 19, 2018)
Written on Monday, 09 April 2018 15:38Lab of cancer biology and other groups of the Deparment of Biomedicine (groups of Molecular Pathology, RNA Biology, and Human Genetics) had a day full…
Successful grant applications
Written on Monday, 09 April 2018 15:23Successful grant applications Dr. Teesalu was awarded two prestigious grants: (1) ~1M EUR Estonian Research Council grant to peptide-based develop transport systems to cross…
Congratulations to Anne-Mari for successfully defending her PhD thesis!
Written on Monday, 04 December 2017 14:03Anne-Mari Anton Willmore successfully defended her Ph.D. thesis „Silver nanoparticles for cancer research“ on November 17th, 2917. Her thesis dealt with the development of silver…
Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease
Written on Thursday, 23 November 2017 09:22Mann AP, Scodeller P, Hussain S, Braun GB, Mölder T, Toome K, Ambasudhan R, Teesalu T, Lipton SA, Ruoslahti E. Nat Commun. 2017 Nov 10;8(1):1403.…Read more...
Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide
Written on Thursday, 23 November 2017 09:18Scodeller P, Simón-Gracia L, Kopanchuk S, Tobi A, Kilk K, Säälik P, Kurm K, Squadrito ML, Kotamraju VR, Rinken A, De Palma M, Ruoslahti E,…Read more...
JanuaryHigh infiltration of CD206+ cells in human breast tumorsImmunohistochemical staining of human CD206 (brown) with nuclear counterstain (Hematoxilin, in dark blue). Authors: Anni Lepland and Pablo Scodeller.
DecemberLong persistence of an M2 TAM internalizing peptide in breast tumorsAn M2 macrophage binding peptide (green) identified in our lab using phage display remains inside M2 TAMs (red) at least 24 hours after systemic administration in a mouse model of…
JuneLinear TT1 peptide-coupled FAM-labeled iron oxide nanoparticles home to blood vessels of subcutaneous U87 tumor xenograftLinear TT1 peptide-coupled FAM-labeled iron oxide nanoparticles (green) home to blood vessels (red) of subcutaneous U87 tumor xenograft. Cell nuclei are stained with DAPI (blue). Scale bar – 50 µm.…